Weekly Investment Analysts’ Ratings Changes for GeneDx (WGS)

Several brokerages have updated their recommendations and price targets on shares of GeneDx (NASDAQ: WGS) in the last few weeks:

• 5/5/2026 – GeneDx had its “buy” rating reaffirmed by Craig Hallum.
• 5/5/2026 – GeneDx was given a new $75.00 price target by Canaccord Genuity Group Inc..
• 5/5/2026 – GeneDx had its “overweight” rating reaffirmed by Wells Fargo & Company. They now have a $75.00 price target on the stock, down from $155.00.
• 5/5/2026 – GeneDx had its price target lowered by Guggenheim from $100.00 to $70.00. They now have a “buy” rating on the stock.
• 5/5/2026 – GeneDx had its price target lowered by BTIG Research from $170.00 to $90.00. They now have a “buy” rating on the stock.
• 4/24/2026 – GeneDx was downgraded by Zacks Research from “strong-buy” to “hold”.
• 4/20/2026 – GeneDx was given a new $100.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 3/30/2026 – GeneDx had its price target lowered by Guggenheim from $170.00 to $100.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other news, CFO Kevin Feeley sold 392 shares of the business’s stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total value of $25,554.48. Following the completion of the sale, the chief financial officer directly owned 34,942 shares in the company, valued at $2,277,868.98. The trade was a 1.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Bryan Dechairo sold 5,961 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $85.70, for a total value of $510,857.70. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 109,989 shares of company stock valued at $7,888,023 over the last ninety days. 29.60% of the stock is owned by corporate insiders.

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.